Haemophilus

Haemophilus is a genus of small, Gram-negative, facultatively anaerobic coccobacilli that inhabit the upper respiratory tract, oral cavity, and gastrointestinal tract. The genus name literally means "blood-loving" — a direct reference to its absolute requirement for heme-derived growth factors (X factor, hemin) and NAD (V factor) that it cannot synthesize on its own. This metal dependency makes Haemophilus a revealing indicator of iron ecology across body sites.

While H. influenzae dominates clinical attention as a respiratory pathogen, the species most commonly encountered in gut microbiome studies is Haemophilus parainfluenzae, a commensal of the oropharynx that appears across esophageal, gastric, and intestinal niches. Its enrichment in inflammatory conditions of the esophagus and gut positions it as a marker of oral-gut microbial translocation and disrupted mucosal immunity.

Metal Dependencies

Haemophilus species are defined by their dependence on iron in the form of heme and hemin:

  • They lack the biosynthetic pathway for protoporphyrin IX and therefore cannot produce heme de novo. Instead, they scavenge free heme, hemoglobin, and hemoglobin-haptoglobin complexes from the host environment.
  • Iron acquisition systems include TonB-dependent outer membrane receptors for heme and transferrin binding proteins (Tbp1/Tbp2) that strip iron from host transferrin.
  • This dependency means Haemophilus thrives in iron-rich, heme-available environments — precisely the conditions found in inflamed mucosa where tissue damage liberates heme from lysed red blood cells.

The genus thus acts as a biological indicator of heme availability: where Haemophilus expands, free heme is abundant, suggesting mucosal inflammation and barrier breakdown.

Key Enzymes and Virulence Factors

  • Tryptophanase: Haemophilus is among the genera that produce indole from tryptophan. Indole and its derivatives (indoxyl sulfate, indole-3-acetic acid) activate the aryl hydrocarbon receptor (ahr) and influence vascular inflammation, making Haemophilus tryptophan metabolism relevant to cardiovascular disease ([1], expert-opinion).
  • Catalase and oxidase: Enable survival in oxygen-variable environments from the aerobic oral cavity to the microaerobic esophagus to the anaerobic distal gut.
  • IgA1 protease: Cleaves human secretory IgA1, subverting mucosal immune defenses and facilitating colonization of inflamed epithelia.

Ecological Role

Haemophilus occupies a distinctive niche as an oral-esophageal-gut bridging organism. Its presence in fecal samples often reflects translocation from the oral cavity through the esophagus, a process amplified by:

  • Gastroesophageal reflux: Acid suppression with proton pump inhibitors raises gastric pH, permitting oral microbes like Haemophilus to survive transit ([2], systematic-review).
  • Mucosal inflammation: Haemophilus was significantly increased in untreated eosinophilic esophagitis (EoE) compared with normal subjects, with increased bacterial load regardless of treatment status ([3], cross-sectional).
  • Disrupted mucosal immunity: In conditions where secretory IgA is impaired or overwhelmed, Haemophilus IgA1 protease activity facilitates persistence.

In the healthy gut, Haemophilus is typically a low-abundance member of the community. Its expansion signals a shift toward a more oxygen-tolerant, oral-type community — often at the expense of strict anaerobes like faecalibacterium prausnitzii and roseburia.

Conditions Associated

Enriched in:

  • Eosinophilic esophagitis: Significantly increased in untreated EoE, associated with eosinophilic mucosal inflammation and increased bacterial load ([3], cross-sectional).
  • Multiple sclerosis: H. parainfluenzae enriched in RRMS patients alongside Veillonella rogosae; beta diversity significantly different from healthy controls ([4], prospective-cohort, n=296).
  • GERD/esophageal reflux: Prevotella and Haemophilus dominant in GERD oral samples, consistent with the oral-esophageal translocation hypothesis ([2], systematic-review).
  • Crohn's disease: H. parainfluenzae identified as one of three cross-study reproducible species in IBD metagenomics ([5], cross-sectional).
  • Pancreatic cancer: Identified in fecal microbiota of PC patients alongside Lactobacillus and Streptococcus; part of a Random Forest classifier with AUC 82.5% ([6], expert-opinion).

Depleted in:

  • Schizophrenia: Among 18 genera depleted in first-episode drug-naive schizophrenia patients; part of a 10-biomarker panel achieving AUC 0.879 for diagnosis. After 24 weeks of risperidone treatment, alpha diversity improved but remained below healthy baseline ([7], prospective-cohort, n=214).

Key Studies

StudyFindingEvidence Level
[3]Haemophilus significantly increased in untreated EoE vs normalCross-sectional
[4]H. parainfluenzae enriched in RRMS (n=296)Prospective cohort
[7]Depleted in schizophrenia; part of diagnostic biomarker panelProspective cohort
[1]Indole producer linking tryptophan metabolism to CVDExpert opinion
[5]Cross-study reproducible IBD speciesCross-sectional

Cross-References

  • iron — heme dependency as ecological driver
  • ahr — indole activation of aryl hydrocarbon receptor
  • streptococcus — co-occurring oral-translocation genus
  • veillonella — co-enriched in MS and esophageal conditions
  • gerd — acid suppression enabling oral-gut translocation
  • multiple sclerosis — neuroinflammatory condition with H. parainfluenzae enrichment
  • tryptophan metabolism — indole production pathway

References (9)

  1. Nadja Paeslack, Maximilian Mimmler, Stefanie Becker et al. (2022). Microbiota-derived tryptophan metabolites in vascular inflammation and cardiovascular disease. Amino Acids. doi:10.1007/s00726-022-03161-5
  2. Alageel AA, Alomran DA, Alharbi HB et al. (2025). Alageel 2025 — Examining the Microbiome Composition in Patients with Gastroesophageal Reflux Disease: A Systematic Review. TPM (The Primary Care Companion for CNS Disorders)
  3. Harris JK, Fang R, Wagner BD et al. (2015). Esophageal Microbiome in Eosinophilic Esophagitis. PLoS ONE. doi:10.1371/journal.pone.0128346
  4. Thirion F, Sellebjerg F, Fan Y et al. (2023). The Gut Microbiota in Multiple Sclerosis Varies with Disease Activity. Genome Medicine. doi:10.1186/s13073-022-01148-1
  5. Kang DY, Park JL, Yeo MK et al. (2023). Diagnosis of Crohn's Disease and Ulcerative Colitis Using the Microbiome. BMC Microbiology. doi:10.1186/s12866-023-03084-5
  6. Ghazaleh Pourali, Danial Kazemi, Amir Shayan Chadeganipour et al. (2024). Microbiome as a biomarker and therapeutic target in pancreatic cancer. BMC Microbiology. doi:10.1186/s12866-023-03166-4
  7. Yuan X, Wang Y, Li X et al. (2021). Gut Microbial Biomarkers for the Treatment Response in First-Episode, Drug-Naive Schizophrenia: A 24-Week Follow-Up Study. Translational Psychiatry. doi:10.1038/s41398-021-01531-3
  8. Liu Y, Yu J, Yang Y et al. (2024). Investigating the causal relationship of gut microbiota with GERD and BE: a bidirectional mendelian randomization. BMC Genomics. doi:10.1186/s12864-024-10377-0
  9. Liu J, Qin X, Lin B et al. (2022). Analysis of gut microbiota diversity in Hashimoto's thyroiditis patients. BMC Microbiology. doi:10.1186/s12866-022-02739-z